Activation of mTORC1 disrupted LDL receptor pathway: A potential new mechanism for the progression of non-alcoholic fatty liver disease

International Journal of Biochemistry and Cell Biology

Volumn 61, Issue , 2015, Pages 8-19

  Liu, Jing ^a   Ma, Kun Ling ^a   Zhang, Yang ^a   Wu, Yu ^a   Hu, Ze Bo ^a   Lv, Lin Li ^a   Tang, Ri Ning ^a   Liu, Hong ^a   Ruan, Xiong Zhong ^b   Liu, Bi Cheng ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cholesterol homeostasis; Inflammation; Low density lipoprotein receptor; Mammalian target of rapamycin complex 1; Non alcoholic fatty liver disease

Indexed keywords

APOLIPOPROTEIN E; CARRIER PROTEINS AND BINDING PROTEINS; CASEIN; HIGH DENSITY LIPOPROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; RAPAMYCIN; S6 KINASE; SERINE PROTEINASE; SREBP CLEAVAGE ACTIVATING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STIMULATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; ENDOPLASMIC RETICULUM; ENZYME INDUCTION; FEEDBACK SYSTEM; GENE SILENCING; GENETIC TRANSCRIPTION; GOLGI COMPLEX; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID BLOOD LEVEL; LIPID STORAGE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE COURSE; GENETIC TRANSFECTION; INFLAMMATION; KNOCKOUT MOUSE; LIPID METABOLISM; METABOLISM; PATHOLOGY;

EUKARYOTA; MAMMALIA; MUS;

ANIMALS; DISEASE PROGRESSION; HEP G2 CELLS; HUMANS; INFLAMMATION; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, LDL; TOR SERINE-THREONINE KINASES; TRANSFECTION; UP-REGULATION;

EID: 84922245560     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2015.01.011     Document Type: Article

References (38)

1. Ai D, Baez JM, Jiang H, Conlon DM, Hernandez-Ono A, Frank-Kamenetsky M, et al. Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obesemice. J Clin Invest 2012a;5:1677-87.
2. Ai D, Chen C, Han S, Ganda A, Murphy AJ, Haeusler R, et al. Regulation of hepatic LDLreceptors by mTORC1 and PCSK9 in mice. J Clin Invest 2012b;4:1262-70.
3. Basso MD, Nambi P, Adelman SJ. Effect of sirolimus on the cholesterol content of aortic arch in ApoE knockout mice. Transplant Proc 2003;8:3136-8.
4. Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholicfatty liver disease. Clin Exp Gastroenterol 2014;7:221-39.
5. Calvert VS, Collantes R, Elariny H, Afendy A, Baranova A, Mendoza M, et al. A systemsbiology approach to the pathogenesis of obesity-related nonalcoholic fatty liverdisease using reverse phase protein microarrays for multiplexed cell signalinganalysis. Hepatology 2007;1:166-72.
6. Das A, Durrant D, Koka S, Salloum FN, Xi L, Kukreja RC. Mammalian target ofrapamycin (mTOR) inhibition with rapamycin improves cardiac function in type2 diabetic mice: potential role of attenuated oxidative stress and altered con-tractile protein expression. J Biol Chem 2014;7:4145-60.
7. Elloso MM, Azrolan N, Sehgal SN, Hsu PL, Phiel KL, Kopec CA, et al. Protective effectof the immunosuppressant sirolimus against aortic atherosclerosis in apo e-deficient mice. Am J Transplant 2003;5:562-9.
8. Goh VJ, Silver DL. The lipid droplet as a potential therapeutic target in NAFLD. SeminLiver Dis 2013;4:312-20.
9. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging iden-tity and importance. J Hepatol 1998;3:495-501.
10. Kahan BD, Yakupoglu YK, Schoenberg L, Knight RJ, Katz SM, Lai D, et al. Low inci-dence of malignancy among sirolimus/cyclosporine-treated renal transplantrecipients. Transplantation 2005;6:749-58.
11. Lagace TA, Curtis DE, Garuti R, Mcnutt MC, Park SW, Prather HB, et al. Secreted PCSK9decreases the number of LDL receptors in hepatocytes and in livers of parabioticmice. J Clin Invest 2006;11:2995-3005.
12. Lambert G, Charlton F, Rye KA, Piper DE. Molecular basis of PCSK9 function. Atherosclerosis 2009;1:1-7.
13. Liu J, Ma KL, Gao M, Wang CX, Ni J, Zhang Y, et al. Inflammation disrupts the LDLreceptor pathway and accelerates the progression of vascular calcification inESRD patients. PLoS ONE 2012;10:e47217.
14. Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Sirolimus modifiescholesterol homeostasis in hepatic cells: a potential molecular mechanism forsirolimus-associated dyslipidemia. Transplantation 2007a;8:1029-36.
15. Ma KL, Ruan XZ, Powis SH, Moorhead JF, Varghese Z. Anti-atherosclerotic effectsof sirolimus on human vascular smooth muscle cells. Am J Physiol Heart CircPhysiol 2007b;6:H2721-8.
16. Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Inflammatory stressexacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology 2008;3:770-81.
17. Ma KL, Varghese Z, Ku Y, Powis SH, Chen Y, Moorhead JF, et al. Sirolimus inhibitsendogenous cholesterol synthesis induced by inflammatory stress in humanvascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2010;6:H1646-51.
18. Ma KL, Liu J, Wang CX, Ni J, Zhang Y, Wu Y, et al. Activation of mTOR modulatesSREBP-2 to induce foam cell formation through increased retinoblastoma pro-tein phosphorylation. Cardiovasc Res 2013;3:450-60.
19. Martinet W, De LH, De Meyer GR. mTOR inhibition: a promising strategy for stabi-lization of atherosclerotic plaques. Atherosclerosis 2014;2:601-7.
20. Mathe D, Adam R, Malmendier C, Gigou M, Lontie JF, Dubois D, et al. Prevalence ofdyslipidemia in liver-transplant recipients. Transplantation 1992;1:167-8.
21. Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis ofnon-alcoholic steatohepatitis. Prog Lipid Res 2013;1:175-91.
22. Naoum JJ, Woodside KJ, Zhang S, Rychahou PG, Hunter GC. Effects of rapamycin onthe arterial inflammatory response in atherosclerotic plaques in Apo-E knockoutmice. Transplant Proc 2005;4:1880-4.
23. Nohturfft A, DeBose-Boyd RA, Scheek S, Goldstein JL, Brown MS. Sterols regulatecycling of SREBP cleavage-activating protein (SCAP) between endoplasmic retic-ulum and Golgi. Proc Natl Acad Sci U S A 1999;20:11235-40.
24. Owen JL, Zhang Y, Bae SH, Farooqi MS, Liang G, Hammer RE, et al. Insulin stimulationof SREBP-1c processing in transgenic rat hepatocytes requires p70 S6-kinase.Proc Natl Acad Sci U S A 2012;40:16184-9.
25. Pakala R, Stabile E, Finegold AA, Hellinga D, Seabron R, Baffour R, et al. Oral rapamycinattenuates atherosclerotic plaque progression in ApoE knockout mice. Circulation 2004;17:53.
26. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, et al. mTORcomplex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011;3:408-20.
27. Ruan XZ, Moorhead JF, Tao JL, Ma KL, Wheeler DC, Powis SH, et al. Mechanismsof dysregulation of low-density lipoprotein receptor expression in vascularsmooth muscle cells by inflammatory cytokines. Arterioscler Thromb Vasc Biol2006;5:1150-5.
28. Ruan XZ, Moorhead JF, Varghese Z. Lipid redistribution in renal dysfunction. KidneyInt 2008;4:407-9.
29. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1(NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci US A 2003;3:928-33.
30. Sinha RA, Farah BL, Singh BK, Siddique MM, Li Y, Wu Y, et al. Caffeine stimulates hep-atic lipid metabolism by the autophagy-lysosomal pathway in mice. Hepatology 2014;4:1366-80.
31. Sirinian MI, Belleudi F, Campagna F, Ceridono M, Garofalo T, Quagliarini F, et al. Adap-tor protein ARH is recruited to the plasma membrane by low density lipoprotein(LDL) binding and modulates endocytosis of the LDL/LDL receptor complex inhepatocytes. J Biol Chem 2005;46:38416-23.
32. Soliman GA. The integral role of mTOR in lipid metabolism. Cell Cycle 2011;6:861-2.
33. Wang BT, Ducker GS, Barczak AJ, Barbeau R, Erle DJ, Shokat KM. The mammaliantarget of rapamycin regulates cholesterol biosynthetic gene expression andexhibits a rapamycin-resistant transcriptional profile. Proc Natl Acad Sci U SA 2011;37:15201-6.
34. Wang Y, Huang Y, Hobbs HH, Cohen JC. Molecular characterization of proproteinconvertase subtilisin/kexin type 9-mediated degradation of the LDLR. J Lipid Res 2012;9:1932-43.
35. Weichhart T. Mammalian target of rapamycin: a signaling kinase for every aspect ofcellular life. Methods Mol Biol 2012;821:1-14.
36. Xiao J, Guo R, Fung ML, Liong EC, Chang RC, Ching YP, et al. Garlic-derived S-allylmercaptocysteine ameliorates nonalcoholic fatty liver disease in a rat modelthrough inhibition of apoptosis and enhancing autophagy. Evid Based Complem Alternat Med 2013;2013:642920.
37. Yang Q, Guan KL. Expanding mTOR signaling. Cell Res 2007;8:666-81.
38. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, et al. Binding ofproprotein convertase subtilisin/kexin type 9 to epidermal growth factor-likerepeat A of low density lipoprotein receptor decreases receptor recycling andincreases degradation. J Biol Chem 2007;25:18602-12.